Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera Inc.

Natera Inc. (($NTRA)) announced an update on their ongoing clinical study. The FIND-CRC study, officially titled ‘Evaluation of the Natera Colorect...

Natera’s FIND-CRC Study: A Potential Game-Changer in Colorectal Cancer Screening

TD Cowen analyst Daniel Brennan maintained a Buy rating on Natera on October 19 and set a price target of $215.00. The company’s shares closed toda...

Current Quarter	$-0.44	Next Quarter	$-0.46
Current Year	$-2.28	Next Year	$-1.29
QoQ Growth	-4.5%	YoY Growth	+43.4%
3Y EPS CAGR	+33.5%	Target Price	$224.84
Consensus	Buy	Upside	-2.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NTRA	$230.63	+2.25%	2.87M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NTRA	$230.63	+2.3%	2.87M
3
4
5
6

NTRA

NTRA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Natera Inc. Data in Excel

Get Natera Inc. Data in Excel